UCB is a global biopharmaceutical company, with a focus on neurology and immunology.
Our business is strong. Total revenue grew to €4.2 billion in 2016. We are more than 7,700 people in all four corners of the globe, inspired by patients and driven by science.
Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline.
At UCB, we put our heart, soul and skills into making a difference for people living with severe disease. Working together to push the boundaries, we blend the best of our talents to unlock innovation. Will you join us in our pioneering adventure?